Tenet Healthcare's stock is in a broad uptrend over the past year, with a 1-year price change of +17.6%, though it has experienced significant volatility. The current price of $204.25 sits at 46.7% of its 52-week range ($146.60 low to $247.21 high), indicating it is closer to the midpoint than the extremes. This positioning suggests the stock is in a recovery phase after a sharp decline from its highs, but has not yet reclaimed the upper end of the range, implying cautious optimism rather than full momentum. The 52-week low of $146.60 and high of $247.21 provide clear reference points for support and resistance. Short-term momentum has been strong, with a 1-month price change of +24.0% and a 3-month change of +4.6%, showing a sharp acceleration in recent weeks. This contrasts with the 1-year trend, which has been positive but choppy, and the 6-month change of +1.5% indicates that the stock was essentially flat before the recent surge. The divergence between the strong 1-month rally and the tepid 6-month performance suggests a potential trend reversal or a mean-reversion bounce from oversold conditions, rather than a sustained new uptrend. The stock's beta of 1.266 indicates it is 26.6% more volatile than the S&P 500, meaning it amplifies market moves. The 52-week low of $146.60 serves as key support, while the 52-week high of $247.21 is the major resistance. A breakout above $247.21 would signal a resumption of the long-term uptrend, while a breakdown below $146.60 would indicate a bearish reversal. The recent rally from the June low of $161.37 to $204.25 represents a 26.6% gain, but the stock remains 17.4% below its 52-week high, suggesting room to run if momentum persists.

Tenet Healthcare's revenue has shown steady growth, with the most recent quarterly revenue (Q4 2025) of $5.527 billion, up 8.97% year-over-year from $5.072 billion in Q4 2024. Over the trailing four quarters, revenue has grown from $5.072 billion (Q4 2024) to $5.527 billion (Q4 2025), indicating a consistent upward trajectory. However, Q1 2026 revenue of $5.227 billion missed expectations due to an unfavorable patient insurance mix, highlighting that growth is not linear. The Ambulatory Care segment contributed $1.433 billion in the most recent period, showing the importance of outpatient services. The overall growth trend supports the investment case, but the mix shift toward lower-revenue payer types is a headwind. Tenet is profitable, with net income of $371 million in Q4 2025 and a net margin of 6.7%. Gross margin has been volatile, ranging from 41.5% in Q4 2025 to 82.3% in Q2 2025, reflecting the impact of payer mix and cost structure. Operating margin was 15.4% in Q4 2025, down from 18.1% in Q1 2025, indicating some compression. However, the company has consistently generated positive net income over the past eight quarters, with EPS of $4.25 in Q4 2025. The trajectory is positive, but margin stability is key to the investment thesis. Tenet's balance sheet shows a debt-to-equity ratio of 3.12, which is high but typical for the hospital industry. Free cash flow (FCF) was $367 million in Q4 2025, and trailing twelve-month FCF is $2.53 billion, indicating strong cash generation. The company has $2.883 billion in cash at the end of Q4 2025, providing liquidity. Return on equity (ROE) is 33.3%, reflecting efficient use of equity, but the high leverage amplifies returns. The current ratio of 1.76 suggests adequate short-term liquidity. Overall, Tenet generates sufficient cash to fund operations and capital expenditures, but the high debt load requires monitoring.